(Bloomberg) -- Novo Nordisk A/S signed a deal worth as much as €1.165 billion ($1.3 billion) with Sweden's Nanexa AB, the latest in a string of small acquisitions as the Danish company tries to ensure it can grow through a looming patent cliff. Most Read from Bloomberg China Is Holding Sensitive F-35 Parts Diverted to Hong Kong Morgan Stanley Rushes to Check Fallout After Deal List Leak Meta Debuts Dedicated 'Charm' Device for Using Muse AI Meta Launches Lightweight $1,299 VR Headset That Looks Like Glasses Bond Selloff Deepens After 30-Year Yield Hits Highest Since 2004 The agreement gives the Danish pharmaceutical giant a global exclusive license to Nanexa's Atomic Layer Deposition drug delivery technology platform it can use for obesity and...
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.